The DOI matches its Crossref record; 210 of the 210 references it cites were found in a registry or an index.
Antibody–Drug Conjugates for Cancer Therapy
Open accessAbstract
Antibody–drug conjugates (ADCs) are novel drugs that exploit the specificity of a monoclonal antibody (mAb) to reach target antigens expressed on cancer cells for the delivery of a potent cytotoxic payload. ADCs provide a unique opportunity to deliver drugs to tumor cells while minimizing toxicity to normal tissue, achieving wider therapeutic windows and enhanced pharmacokinetic/pharmacodynamic properties. To date, nine ADCs have been approved by the FDA and more than 80 ADCs are under clinical development worldwide. In this paper, we provide an overview of the biology and chemistry of each component of ADC design. We briefly discuss the clinical experience with approved ADCs and the various pathways involved in ADC resistance. We conclude with perspectives about the future development of the next generations of ADCs, including the role of molecular imaging in drug development.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Trastuzumab emtansine for HER2-positive advanced breast cancer
Verma, S., Miles, D., Gianni, L., Krop, I. E., Welslau, M., Baselga, J., Pegram, M., Oh, D.-Y., Diéras, V., Guardino, E., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1209124 · Cited by 3,834
Regulated portals of entry into the cell
Conner, S. D., & Schmid, S. L. (2003) · Nature · doi:10.1038/nature01451 · Cited by 3,805
Targeting multidrug resistance in cancer
Szakács, G., Paterson, J. K., Ludwig, J. A., Booth-Genthe, C., & Gottesman, M. M. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd1984 · Cited by 3,609
IgG Subclasses and Allotypes: From Structure to Effector Functions
Vidarsson, G., Dekkers, G., & Rispens, T. (2014) · Frontiers in Immunology · doi:10.3389/fimmu.2014.00520 · Cited by 2,667
Mechanisms of Cancer Drug Resistance
Gottesman, M. M. (2002) · Annual Review of Medicine · doi:10.1146/annurev.med.53.082901.103929 · Cited by 2,643
FcRn: the neonatal Fc receptor comes of age
Roopenian, D. C., & Akilesh, S. (2007) · Nature Reviews Immunology · doi:10.1038/nri2155 · Cited by 2,346
Scott, A. M., Wolchok, J. D., & Old, L. J. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3236 · Cited by 2,160
Self-citationTrastuzumab deruxtecan in previously treated HER2-positive breast cancer
Modi, S., Saura, C., Yamashita, T., Park, Y. H., Kim, S.-B., Tamura, K., Andre, F., Iwata, H., Ito, Y., Tsurutani, J., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1914510 · Cited by 2,006
Microtubule-binding agents: a dynamic field of cancer therapeutics
Dumontet, C., & Jordan, M. A. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd3253 · Cited by 1,718
Targeting HER2-Positive Breast Cancer with Trastuzumab-DM1, an Antibody–Cytotoxic Drug Conjugate
Lewis Phillips, G. D., Li, G., Dugger, D. L., Crocker, L. M., Parsons, K. L., Mai, E., Blättler, W. A., Lambert, J. M., Chari, R. V. J., Lutz, R. J., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-1776 · Cited by 1,676
Younes, A., Gopal, A. K., Smith, S. E., Ansell, S. M., Rosenblatt, J. D., Savage, K. J., Ramchandren, R., Bartlett, N. L., Cheson, B. D., de Vos, S., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.38.0410 · Cited by 1,529
Inotuzumab Ozogamicin versus Standard Therapy for Acute Lymphoblastic Leukemia
Kantarjian, H. M., DeAngelo, D. J., Stelljes, M., Martinelli, G., Liedtke, M., Stock, W., Gökbuget, N., O’Brien, S., Wang, K., Wang, T., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1509277 · Cited by 1,413
Saito, G., Swanson, J. A., & Lee, K.-D. (2003) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(02)00179-5 · Cited by 1,407
Site-specific conjugation of a cytotoxic drug to an antibody improves the therapeutic index
Junutula, J. R., Raab, H., Clark, S., Bhakta, S., Leipold, D. D., Weir, S., Chen, Y., Simpson, M., Tsai, S. P., Dennis, M. S., et al. (2008) · Nature Biotechnology · doi:10.1038/nbt.1480 · Cited by 1,382
Effects of Drug Loading on the Antitumor Activity of a Monoclonal Antibody Drug Conjugate
Hamblett, K. J., Senter, P. D., Chace, D. F., Sun, M. M. C., Lenox, J., Cerveny, C. G., Kissler, K. M., Bernhardt, S. X., Kopcha, A. K., Zabinski, R. F., et al. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-0789 · Cited by 1,247
Ogitani, Y., Aida, T., Hagihara, K., Yamaguchi, J., Ishii, C., Harada, N., Soma, M., Okamoto, H., Oitate, M., Arakawa, S., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-2822 · Cited by 1,177
Castaigne, S., Pautas, C., Terré, C., Raffoux, E., Bordessoule, D., Bastie, J.-N., Legrand, O., Thomas, X., Turlure, P., Reman, O., et al. (2012) · The Lancet · doi:10.1016/s0140-6736(12)60485-1 · Cited by 1,015
Pro, B., Advani, R., Brice, P., Bartlett, N. L., Rosenblatt, J. D., Illidge, T., Matous, J., Ramchandren, R., Fanale, M., Connors, J. M., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.38.0402 · Cited by 997
Bracci, L., Schiavoni, G., Sistigu, A., & Belardelli, F. (2014) · Cell Death & Differentiation · doi:10.1038/cdd.2013.67 · Cited by 928
The role of glutathione in cancer
Balendiran, G. K., Dabur, R., & Fraser, D. (2004) · Cell Biochemistry and Function · doi:10.1002/cbf.1149 · Cited by 927
Sacituzumab govitecan-hziy in refractory metastatic triple-negative breast cancer
Bardia, A., Mayer, I. A., Vahdat, L. T., Tolaney, S. M., Isakoff, S. J., Diamond, J. R., O’Shaughnessy, J., Moroose, R. L., Santin, A. D., Abramson, V. G., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1814213 · Cited by 874
Approval summary: gemtuzumab ozogamicin in relapsed acute myeloid leukemia.
Bross, P. F., Beitz, J. G., Chen, G., Chen, X., Duffy, E. J., Kieffer, L. V., Roy, S., Sridhara, R. N., Rahman, A., Williams, G., et al. (2001) · PubMed · Cited by 855
Antibody–drug conjugates for cancer
Chau, C. H., Steeg, P. S., & Figg, W. D. (2019) · The Lancet · doi:10.1016/s0140-6736(19)31774-x · Cited by 816
Targeted Cancer Therapy: Conferring Specificity to Cytotoxic Drugs
Chari, R. V. J. (2008) · Accounts of Chemical Research · doi:10.1021/ar700108g · Cited by 815
Lonial, S., Lee, H. C., Badros, A., Trudel, S., Nooka, A. K., Chari, A., Abdallah, A.-O., Callander, N., Lendvai, N., Sborov, D., et al. (2020) · The Lancet Oncology · doi:10.1016/s1470-2045(19)30788-0 · Cited by 812
Pharmacogenetics and the practice of medicine
Roses, A. D. (2000) · Nature · doi:10.1038/35015728 · Cited by 810
Brentuximab Vedotin with Chemotherapy for Stage III or IV Hodgkin’s Lymphoma
Connors, J. M., Jurczak, W., Straus, D. J., Ansell, S. M., Kim, W. S., Gallamini, A., Younes, A., Alekseev, S., Illés, Á., Picardi, M., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1708984 · Cited by 789
Antibody–Drug Conjugates: A Comprehensive Review
Khongorzul, P., Ling, C. J., Khan, F. U., Ihsan, A. U., & Zhang, J. (2020) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-19-0582 · Cited by 787
Polatuzumab Vedotin in Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Sehn, L. H., Herrera, A. F., Flowers, C. R., Kamdar, M. K., McMillan, A., Hertzberg, M., Assouline, S., Kim, T. M., Kim, W. S., Ozcan, M., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.19.00172 · Cited by 774
Antibody-Drug Conjugates in Cancer Therapy
Sievers, E. L., & Senter, P. D. (2013) · Annual Review of Medicine · doi:10.1146/annurev-med-050311-201823 · Cited by 770
Burris, H. A., Rugo, H. S., Vukelja, S. J., Vogel, C. L., Borson, R. A., Limentani, S., Tan-Chiu, E., Krop, I. E., Michaelson, R. A., Girish, S., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.29.5865 · Cited by 764
Senter, P. D., & Sievers, E. L. (2012) · Nature Biotechnology · doi:10.1038/nbt.2289 · Cited by 763
Moskowitz, C. H., Nademanee, A., Masszi, T., Agura, E., Holowiecki, J., Abidi, M. H., Chen, A. I., Stiff, P., Gianni, A. M., Carella, A., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(15)60165-9 · Cited by 742
Horwitz, S., O'Connor, O. A., Pro, B., Illidge, T., Fanale, M., Advani, R., Bartlett, N. L., Christensen, J. H., Morschhauser, F., Domingo-Domenech, E., et al. (2019) · The Lancet · doi:10.1016/s0140-6736(18)32984-2 · Cited by 739
Challita-Eid, P. M., Satpayev, D., Yang, P., An, Z., Morrison, K., Shostak, Y., Raitano, A., Nadell, R., Liu, W., Lortie, D. R., et al. (2016) · Cancer Research · doi:10.1158/0008-5472.can-15-1313 · Cited by 724
Building better monoclonal antibody-based therapeutics
Weiner, G. J. (2015) · Nature Reviews Cancer · doi:10.1038/nrc3930 · Cited by 712
Site-specific antibody drug conjugates for cancer therapy
Panowski, S., Bhakta, S., Raab, H., Polakis, P., & Junutula, J. R. (2014) · mAbs · doi:10.4161/mabs.27022 · Cited by 676
Burnett, A. K., Hills, R. K., Milligan, D., Kjeldsen, L., Kell, J., Russell, N. H., Yin, J. A. L., Hunter, A., Goldstone, A. H., & Wheatley, K. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.31.4310 · Cited by 657
HER2: Biology, Detection, and Clinical Implications
Gutierrez, C., & Schiff, R. (2011) · Archives of Pathology & Laboratory Medicine · doi:10.5858/2010-0454-rar.1 · Cited by 652
Rosenberg, J. E., O’Donnell, P. H., Balar, A. V., McGregor, B. A., Heath, E. I., Yu, E. Y., Galsky, M. D., Hahn, N. M., Gartner, E. M., Pinelli, J. M., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.19.01140 · Cited by 642
Petersdorf, S. H., Kopecky, K. J., Slovak, M., Willman, C., Nevill, T., Brandwein, J., Larson, R. A., Erba, H. P., Stiff, P. J., Stuart, R. K., et al. (2013) · Blood · doi:10.1182/blood-2013-01-466706 · Cited by 638
Davis, C., Naci, H., Gurpinar, E., Poplavska, E., Pinto, A., & Aggarwal, A. (2017) · BMJ · doi:10.1136/bmj.j4530 · Cited by 599
Krop, I. E., Beeram, M., Modi, S., Jones, S. F., Holden, S. N., Yu, W., Girish, S., Tibbitts, J., Yi, J.-H., Sliwkowski, M. X., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.26.2071 · Cited by 595
Trastuzumab emtansine: mechanisms of action and drug resistance
Barok, M., Joensuu, H., & Isola, J. (2014) · Breast Cancer Research · doi:10.1186/bcr3621 · Cited by 595
Hamann, P. R., Hinman, L. M., Hollander, I., Beyer, C. F., Lindh, D., Holcomb, R., Hallett, W., Tsou, H.-R., Upeslacis, J., Shochat, D., et al. (2002) · Bioconjugate Chemistry · doi:10.1021/bc010021y · Cited by 594
Prince, H. M., Kim, Y. H., Horwitz, S. M., Dummer, R., Scarisbrick, J., Quaglino, P., Zinzani, P. L., Wolter, P., Sanches, J. A., Ortiz-Romero, P. L., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)31266-7 · Cited by 588
Erickson, H. K., Park, P. U., Widdison, W. C., Kovtun, Y. V., Garrett, L. M., Hoffman, K., Lutz, R. J., Goldmacher, V. S., & Blättler, W. A. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-4489 · Cited by 584
Redox state of glutathione in human plasma
Jones, D. P., Carlson, J. L., Mody, V. C., Cai, J., Lynn, M. J., & Sternberg, P. (2000) · Free Radical Biology and Medicine · doi:10.1016/s0891-5849(99)00275-0 · Cited by 584
Banerji, U., van Herpen, C. M. L., Saura, C., Thistlethwaite, F., Lord, S., Moreno, V., Macpherson, I. R., Boni, V., Rolfo, C., de Vries, E. G. E., et al. (2019) · The Lancet Oncology · doi:10.1016/s1470-2045(19)30328-6 · Cited by 547
Antibody drug conjugates and bystander killing: is antigen-dependent internalisation required?
Staudacher, A. H., & Brown, M. P. (2017) · British Journal of Cancer · doi:10.1038/bjc.2017.367 · Cited by 540
Krop, I. E., Kim, S.-B., Martin, A. G., LoRusso, P. M., Ferrero, J.-M., Badovinac-Crnjevic, T., Hoersch, S., Smitt, M., & Wildiers, H. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30313-3 · Cited by 531
The cost of biopharmaceutical R&D: is biotech different?
DiMasi, J. A., & Grabowski, H. G. (2007) · Managerial and Decision Economics · doi:10.1002/mde.1360 · Cited by 517
Doronina, S. O., Mendelsohn, B. A., Bovee, T. D., Cerveny, C. G., Alley, S. C., Meyer, D. L., Oflazoglu, E., Toki, B. E., Sanderson, R. J., Zabinski, R. F., et al. (2006) · Bioconjugate Chemistry · doi:10.1021/bc0502917 · Cited by 515
Donaghy, H. (2016) · mAbs · doi:10.1080/19420862.2016.1156829 · Cited by 495
Recent advances in tumor-targeting anticancer drug conjugates
Jaracz, S., Chen, J., Kuznetsova, L. V., & Ojima, I. (2005) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2005.04.084 · Cited by 490
ImmunoPET: Concept, Design, and Applications
Wei, W., Rosenkrans, Z. T., Liu, J., Huang, G., Luo, Q.-Y., & Cai, W. (2020) · Chemical Reviews · doi:10.1021/acs.chemrev.9b00738 · Cited by 484
Antibody–drug conjugates: current status and future directions
Perez, H. L., Cardarelli, P. M., Deshpande, S., Gangwar, S., Schroeder, G. M., Vite, G. D., & Borzilleri, R. M. (2014) · Drug Discovery Today · doi:10.1016/j.drudis.2013.11.004 · Cited by 470
Jain, N., Smith, S. W., Ghone, S., & Tomczuk, B. (2015) · Pharmaceutical Research · doi:10.1007/s11095-015-1657-7 · Cited by 459
LoRusso, P. M., Weiss, D., Guardino, E., Girish, S., & Sliwkowski, M. X. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-0762 · Cited by 444
Tumor inhibitors. LXXIII. Maytansine, a novel antileukemic ansa macrolide from Maytenus ovatus
Kupchan, S. M., Komoda, Y., Court, W. A., Thomas, G. J., Smith, R. M., Karim, A., Gilmore, C. J., Haltiwanger, R. C., & Bryan, R. F. (1972) · Journal of the American Chemical Society · doi:10.1021/ja00759a054 · Cited by 434
Antibody Conjugate Therapeutics: Challenges and Potential
Teicher, B. A., & Chari, R. V. J. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-1417 · Cited by 427
Burnett, A. K., Russell, N. H., Hills, R. K., Kell, J., Freeman, S., Kjeldsen, L., Hunter, A. E., Yin, J., Craddock, C. F., Dufva, I. H., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2012.42.2964 · Cited by 409
Potent antibody drug conjugates for cancer therapy
Senter, P. D. (2009) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2009.03.023 · Cited by 401
Hurvitz, S. A., Dirix, L., Kocsis, J., Bianchi, G. V., Lu, J., Vinholes, J., Guardino, E., Song, C., Tong, B., Ng, V., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.44.9694 · Cited by 392
Kung Sutherland, M. S., Walter, R. B., Jeffrey, S. C., Burke, P. J., Yu, C., Kostner, H., Stone, I., Ryan, M. C., Sussman, D., Lyon, R. P., et al. (2013) · Blood · doi:10.1182/blood-2013-03-491506 · Cited by 391
Krop, I. E., LoRusso, P., Miller, K. D., Modi, S., Yardley, D., Rodriguez, G., Guardino, E., Lu, M., Zheng, M., Girish, S., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.40.5902 · Cited by 366
Amadori, S., Suciu, S., Selleslag, D., Aversa, F., Gaidano, G., Musso, M., Annino, L., Venditti, A., Voso, M. T., Mazzone, C., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.64.0060 · Cited by 362
Gebhart, G., Lamberts, L. E., Wimana, Z., Garcia, C., Emonts, P., Ameye, L., Stroobants, S., Huizing, M., Aftimos, P., Tol, J., et al. (2016) · Annals of Oncology · doi:10.1093/annonc/mdv577 · Cited by 355
Objective responses in relapsed T-cell lymphomas with single-agent brentuximab vedotin
Horwitz, S. M., Advani, R. H., Bartlett, N. L., Jacobsen, E. D., Sharman, J. P., O’Connor, O. A., Siddiqi, T., Kennedy, D. A., & Oki, Y. (2014) · Blood · doi:10.1182/blood-2013-12-542142 · Cited by 352
Recent advances in the construction of antibody–drug conjugates
Chudasama, V., Maruani, A., & Caddick, S. (2016) · Nature Chemistry · doi:10.1038/nchem.2415 · Cited by 352
STEAP: A prostate-specific cell-surface antigen highly expressed in human prostate tumors
Hubert, R. S., Vivanco, I., Chen, E., Rastegar, S., Leong, K., Mitchell, S. C., Madraswala, R., Zhou, Y., Kuo, J., Raitano, A. B., et al. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.25.14523 · Cited by 351
Amiri-Kordestani, L., Blumenthal, G. M., Xu, Q. C., Zhang, L., Tang, S. W., Ha, L., Weinberg, W. C., Chi, B., Candau-Chacon, R., Hughes, P., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-0012 · Cited by 351
Müller, P., Kreuzaler, M., Khan, T., Thommen, D. S., Martin, K., Glatz, K., Savic, S., Harbeck, N., Nitz, U., Gluz, O., et al. (2015) · Science Translational Medicine · doi:10.1126/scitranslmed.aac4925 · Cited by 349
Starodub, A. N., Ocean, A. J., Shah, M. A., Guarino, M. J., Picozzi, V. J., Vahdat, L. T., Thomas, S. S., Govindan, S. V., Maliakal, P. P., Wegener, W. A., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-3321 · Cited by 340
Li, F., Emmerton, K. K., Jonas, M., Zhang, X., Miyamoto, J. B., Setter, J. R., Nicholas, N. D., Okeley, N. M., Lyon, R. P., Benjamin, D. R., et al. (2016) · Cancer Research · doi:10.1158/0008-5472.can-15-1795 · Cited by 340
Immuno-PET: A Navigator in Monoclonal Antibody Development and Applications
van Dongen, G. A. M. S., Visser, G. W. M., Lub-de Hooge, M. N., de Vries, E. G., & Perk, L. R. (2007) · The Oncologist · doi:10.1634/theoncologist.12-12-1379 · Cited by 330
Pharmaceutical Innovation in the 21st Century: New Drug Approvals in the First Decade, 2000–2009
Kaitin, K. I., & DiMasi, J. A. (2011) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2010.286 · Cited by 328
Mitosis is not a key target of microtubule agents in patient tumors
Komlodi-Pasztor, E., Sackett, D., Wilkerson, J., & Fojo, T. (2011) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2010.228 · Cited by 314
Ritchie, M., Tchistiakova, L., & Scott, N. (2013) · mAbs · doi:10.4161/mabs.22854 · Cited by 312
Mechanisms of resistance to trastuzumab emtansine (T-DM1) in HER2-positive breast cancer
Hunter, F. W., Barker, H. R., Lipert, B., Rothé, F., Gebhart, G., Piccart-Gebhart, M. J., Sotiriou, C., & Jamieson, S. M. F. (2020) · British Journal of Cancer · doi:10.1038/s41416-019-0635-y · Cited by 304
Sanchez, E., Li, M., Kitto, A., Li, J., Wang, C. S., Kirk, D. T., Yellin, O., Nichols, C. M., Dreyer, M. P., Ahles, C. P., et al. (2012) · British Journal of Haematology · doi:10.1111/j.1365-2141.2012.09241.x · Cited by 279
Loganzo, F., Tan, X., Sung, M., Jin, G., Myers, J. S., Melamud, E., Wang, F., Diesl, V., Follettie, M. T., Musto, S., et al. (2015) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-14-0862 · Cited by 278
Randomized Phase II Study of BR96-Doxorubicin Conjugate in Patients With Metastatic Breast Cancer
Tolcher, A. W., Sugarman, S., Gelmon, K. A., Cohen, R., Saleh, M., Isaacs, C., Young, L., Healey, D., Onetto, N., & Slichenmyer, W. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.2.478 · Cited by 271
Antibody-Maytansinoid Conjugates Designed to Bypass Multidrug Resistance
Kovtun, Y. V., Audette, C. A., Mayo, M. F., Jones, G. E., Doherty, H., Maloney, E. K., Erickson, H. K., Sun, X., Wilhelm, S., Ab, O., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-3546 · Cited by 266
Girish, S., Gupta, M., Wang, B., Lu, D., Krop, I. E., Vogel, C. L., Burris III, H. A., LoRusso, P. M., Yi, J.-H., Saad, O., et al. (2012) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-011-1817-3 · Cited by 262
New developments for antibody-drug conjugate-based therapeutic approaches
de Goeij, B. E., & Lambert, J. M. (2016) · Current Opinion in Immunology · doi:10.1016/j.coi.2016.02.008 · Cited by 256
Polson, A. G., Calemine-Fenaux, J., Chan, P., Chang, W., Christensen, E., Clark, S., de Sauvage, F. J., Eaton, D., Elkins, K., Elliott, J. M., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-2250 · Cited by 252
Site-specific chemical protein conjugation using genetically encoded aldehyde tags
Rabuka, D., Rush, J. S., deHart, G. W., Wu, P., & Bertozzi, C. R. (2012) · Nature Protocols · doi:10.1038/nprot.2012.045 · Cited by 246
Isotype selection in antibody engineering
Salfeld, J. G. (2007) · Nature Biotechnology · doi:10.1038/nbt1207-1369 · Cited by 239
de Bono, J. S., Concin, N., Hong, D. S., Thistlethwaite, F. C., Machiels, J.-P., Arkenau, H.-T., Plummer, R., Jones, R. H., Nielsen, D., Windfeld, K., et al. (2019) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30859-3 · Cited by 237
Antibody‐Drug Conjugates for the Treatment of Cancer
Flygare, J. A., Pillow, T. H., & Aristoff, P. (2013) · Chemical Biology & Drug Design · doi:10.1111/cbdd.12085 · Cited by 232
Lopus, M., Oroudjev, E., Wilson, L., Wilhelm, S., Widdison, W., Chari, R., & Jordan, M. A. (2010) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-10-0644 · Cited by 232
Mechanisms of Resistance to Antibody–Drug Conjugates
Loganzo, F., Sung, M., & Gerber, H.-P. (2016) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-16-0408 · Cited by 231
Barok, M., Tanner, M., Köninki, K., & Isola, J. (2011) · Breast Cancer Research · doi:10.1186/bcr2868 · Cited by 226
Moore, K. N., Martin, L. P., O’Malley, D. M., Matulonis, U. A., Konner, J. A., Perez, R. P., Bauer, T. M., Ruiz-Soto, R., & Birrer, M. J. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2016.69.9538 · Cited by 226
Elgersma, R. C., Coumans, R. G. E., Huijbregts, T., Menge, W. M. P. B., Joosten, J. A. F., Spijker, H. J., de Groot, F. M. H., van der Lee, M. M. C., Ubink, R., van den Dobbelsteen, D. J., et al. (2015) · Molecular Pharmaceutics · doi:10.1021/mp500781a · Cited by 221
Schwartz, R. S. (2004) · New England Journal of Medicine · doi:10.1056/nejmp048021 · Cited by 221
Potential Mechanisms for Thrombocytopenia Development with Trastuzumab Emtansine (T-DM1)
Uppal, H., Doudement, E., Mahapatra, K., Darbonne, W. C., Bumbaca, D., Shen, B.-Q., Du, X., Saad, O., Bowles, K., Olsen, S., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-2093 · Cited by 218
Kantarjian, H. M., DeAngelo, D. J., Advani, A. S., Stelljes, M., Kebriaei, P., Cassaday, R. D., Merchant, A. A., Fujishima, N., Uchida, T., Calbacho, M., et al. (2017) · The Lancet Haematology · doi:10.1016/s2352-3026(17)30103-5 · Cited by 217
Caveolae-Mediated Endocytosis as a Novel Mechanism of Resistance to Trastuzumab Emtansine (T-DM1)
Sung, M., Tan, X., Lu, B., Golas, J., Hosselet, C., Wang, F., Tylaska, L., King, L., Zhou, D., Dushin, R., et al. (2018) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-17-0403 · Cited by 215
Tubulin Inhibitor-Based Antibody-Drug Conjugates for Cancer Therapy
Chen, H., Lin, Z., Arnst, K., Miller, D., & Li, W. (2017) · Molecules · doi:10.3390/molecules22081281 · Cited by 214
Chen, R., Hou, J., Newman, E., Kim, Y., Donohue, C., Liu, X., Thomas, S. H., Forman, S. J., & Kane, S. E. (2015) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-15-0036 · Cited by 213
Trudel, S., Lendvai, N., Popat, R., Voorhees, P. M., Reeves, B., Libby, E. N., Richardson, P. G., Hoos, A., Gupta, I., Bragulat, V., et al. (2019) · Blood Cancer Journal · doi:10.1038/s41408-019-0196-6 · Cited by 213
de Claro, R. A., McGinn, K., Kwitkowski, V., Bullock, J., Khandelwal, A., Habtemariam, B., Ouyang, Y., Saber, H., Lee, K., Koti, K., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-1803 · Cited by 210
Recent Progress in Understanding the Mechanism of P-Glycoprotein-mediated Drug Efflux
Loo, T. W., & Clarke, D. M. (2005) · Journal of Membrane Biology · doi:10.1007/s00232-005-0792-1 · Cited by 209
Resistance to Antibody–Drug Conjugates
García-Alonso, S., Ocaña, A., & Pandiella, A. (2018) · Cancer Research · doi:10.1158/0008-5472.can-17-3671 · Cited by 208
Fate of Antibody-Drug Conjugates in Cancer Cells
Chalouni, C., & Doll, S. (2018) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-017-0667-1 · Cited by 206
Müller, P., Martin, K., Theurich, S., Schreiner, J., Savic, S., Terszowski, G., Lardinois, D., Heinzelmann-Schwarz, V. A., Schlaak, M., Kvasnicka, H.-M., et al. (2014) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-13-0198 · Cited by 203
Ikeda, H., Hideshima, T., Fulciniti, M., Lutz, R. J., Yasui, H., Okawa, Y., Kiziltepe, T., Vallet, S., Pozzi, S., Santo, L., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-2867 · Cited by 203
Servais, E. L., Colovos, C., Rodriguez, L., Bograd, A. J., Nitadori, J.-I., Sima, C., Rusch, V. W., Sadelain, M., & Adusumilli, P. S. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-2614 · Cited by 202
van der Lee, M. M. C., Groothuis, P. G., Ubink, R., van der Vleuten, M. A. J., van Achterberg, T. A., Loosveld, E. M., Damming, D., Jacobs, D. C. H., Rouwette, M., Egging, D. F., et al. (2015) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-14-0881-t · Cited by 201
Moldenhauer, G., Salnikov, A. V., Lüttgau, S., Herr, I., Anderl, J., & Faulstich, H. (2012) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djs140 · Cited by 199
Phillips, G. D. L., Fields, C. T., Li, G., Dowbenko, D., Schaefer, G., Miller, K., Andre, F., Burris, H. A., Albain, K. S., Harbeck, N., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-0358 · Cited by 198
Ríos-Luci, C., García-Alonso, S., Díaz-Rodríguez, E., Nadal-Serrano, M., Arribas, J., Ocaña, A., & Pandiella, A. (2017) · Cancer Research · doi:10.1158/0008-5472.can-16-3127 · Cited by 197
Lee, L., Bounds, D., Paterson, J., Herledan, G., Sully, K., Seestaller‐Wehr, L. M., Fieles, W. E., Tunstead, J., McCahon, L., Germaschewski, F. M., et al. (2016) · British Journal of Haematology · doi:10.1111/bjh.14145 · Cited by 191
Antibody–drug conjugates for cancer: poised to deliver?
Hughes, B. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd3270 · Cited by 188
Hoffmann, R. M., Coumbe, B. G. T., Josephs, D. H., Mele, S., Ilieva, K. M., Cheung, A., Tutt, A. N., Spicer, J. F., Thurston, D. E., Crescioli, S., et al. (2018) · OncoImmunology · doi:10.1080/2162402x.2017.1395127 · Cited by 188
Targeting LGR5 + cells with an antibody-drug conjugate for the treatment of colon cancer
Junttila, M. R., Mao, W., Wang, X., Wang, B.-E., Pham, T., Flygare, J., Yu, S.-F., Yee, S., Goldenberg, D., Fields, C., et al. (2015) · Science Translational Medicine · doi:10.1126/scitranslmed.aac7433 · Cited by 182
Poruchynsky, M. S., Komlodi-Pasztor, E., Trostel, S., Wilkerson, J., Regairaz, M., Pommier, Y., Zhang, X., Kumar Maity, T., Robey, R., Burotto, M., et al. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1416418112 · Cited by 182
Monoclonal antibodies as immunomodulatory therapy against cancer and autoimmune diseases
Hafeez, U., Gan, H. K., & Scott, A. M. (2018) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2018.05.010 · Cited by 176
Self-citationThe development of pyrrolobenzodiazepines as antitumour agents
Hartley, J. A. (2011) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2011.573477 · Cited by 175
Hassan, R., Blumenschein, G. R., Moore, K. N., Santin, A. D., Kindler, H. L., Nemunaitis, J. J., Seward, S. M., Thomas, A., Kim, S. K., Rajagopalan, P., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.19.02085 · Cited by 173
Stability of IgG isotypes in serum
Correia, I. (2010) · mAbs · doi:10.4161/mabs.2.3.11788 · Cited by 172
Mechanisms of action of therapeutic antibodies for cancer
Redman, J. M., Hill, E. M., AlDeghaither, D., & Weiner, L. M. (2015) · Molecular Immunology · doi:10.1016/j.molimm.2015.04.002 · Cited by 171
Monoclonal antibodies for the treatment of cancer
Shuptrine, C. W., Surana, R., & Weiner, L. M. (2012) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2011.12.009 · Cited by 170
Younes, A., Kim, S., Romaguera, J., Copeland, A., Farial, S. D. C., Kwak, L. W., Fayad, L., Hagemeister, F., Fanale, M., Neelapu, S., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.39.4403 · Cited by 170
Yu, S.-F., Zheng, B., Go, M., Lau, J., Spencer, S., Raab, H., Soriano, R., Jhunjhunwala, S., Cohen, R., Caruso, M., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-2035 · Cited by 168
Sapra, P., Stein, R., Pickett, J., Qu, Z., Govindan, S. V., Cardillo, T. M., Hansen, H. J., Horak, I. D., Griffiths, G. L., & Goldenberg, D. M. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-0204 · Cited by 167
Immunotoxins and Anticancer Drug Conjugate Assemblies: The Role of the Linkage between Components
Dosio, F., Brusa, P., & Cattel, L. (2011) · Toxins · doi:10.3390/toxins3070848 · Cited by 166
Rapid identification of reactive cysteine residues for site-specific labeling of antibody-Fabs
Junutula, J. R., Bhakta, S., Raab, H., Ervin, K. E., Eigenbrot, C., Vandlen, R., Scheller, R. H., & Lowman, H. B. (2008) · Journal of Immunological Methods · doi:10.1016/j.jim.2007.12.011 · Cited by 165
Oroudjev, E., Lopus, M., Wilson, L., Audette, C., Provenzano, C., Erickson, H., Kovtun, Y., Chari, R., & Jordan, M. A. (2010) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-10-0645 · Cited by 164
Skidmore, L., Sakamuri, S., Knudsen, N. A., Hewet, A. G., Milutinovic, S., Barkho, W., Biroc, S. L., Kirtley, J., Marsden, R., Storey, K., et al. (2020) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-19-1004 · Cited by 164
Acquired Resistance to Antibody-Drug Conjugates
Collins, D., Bossenmaier, B., Kollmorgen, G., & Niederfellner, G. (2019) · Cancers · doi:10.3390/cancers11030394 · Cited by 160
Antibody-targeted drugs and drug resistance—Challenges and solutions
Shefet-Carasso, L., & Benhar, I. (2014) · Drug Resistance Updates · doi:10.1016/j.drup.2014.11.001 · Cited by 159
Dowell, J. A., Korth‐Bradley, J., Liu, H., King, S. P., & Berger, M. S. (2001) · The Journal of Clinical Pharmacology · doi:10.1177/00912700122012751 · Cited by 158
Intracellular trafficking of new anticancer therapeutics: antibody–drug conjugates
Kalim, M., Chen, J., Wang, S., Lin, C., Ullah, S., Liang, K., Ding, Q., Chen, S., & Zhan, J.-B. (2017) · Drug Design, Development and Therapy · doi:10.2147/dddt.s135571 · Cited by 158
Scribner, J. A., Brown, J. G., Son, T., Chiechi, M., Li, P., Sharma, S., Li, H., De Costa, A., Li, Y., Chen, Y., et al. (2020) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-20-0116 · Cited by 158
Engineered therapeutic antibodies with improved effector functions
Kubota, T., Niwa, R., Satoh, M., Akinaga, S., Shitara, K., & Hanai, N. (2009) · Cancer Science · doi:10.1111/j.1349-7006.2009.01222.x · Cited by 156
Targeting LGR5 in Colorectal Cancer: therapeutic gold or too plastic?
Morgan, R., Mortensson, E., & Williams, A. C. (2018) · British Journal of Cancer · doi:10.1038/s41416-018-0118-6 · Cited by 153
Current methods for the synthesis of homogeneous antibody–drug conjugates
Sochaj, A. M., Świderska, K. W., & Otlewski, J. (2015) · Biotechnology Advances · doi:10.1016/j.biotechadv.2015.05.001 · Cited by 142
Monoclonal antibody-based molecular imaging strategies and theranostic opportunities
Dammes, N., & Peer, D. (2020) · Theranostics · doi:10.7150/thno.37443 · Cited by 138
Biosynthesis, synthesis, and biological activities of pyrrolobenzodiazepines
Gerratana, B. (2010) · Medicinal Research Reviews · doi:10.1002/med.20212 · Cited by 136
LGR5-Targeted Antibody–Drug Conjugate Eradicates Gastrointestinal Tumors and Prevents Recurrence
Gong, X., Azhdarinia, A., Ghosh, S. C., Xiong, W., An, Z., Liu, Q., & Carmon, K. S. (2016) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-16-0114 · Cited by 130
Onitilo, A. A., Engel, J. M., & Stankowski, R. V. (2014) · Therapeutic Advances in Drug Safety · doi:10.1177/2042098614529603 · Cited by 124
O'Brien, C. L., Cavet, G., Pandita, A., Hu, X., Haydu, L. E., Mohan, S., Toy, K. J., Rivers, C. S., Modrusan, Z. D., Amler, L. C., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-0234 · Cited by 112
Antibody conjugates with unnatural amino acids.
Hallam, T., Wold, E. D., Wahl, A., & Smider, V. V. (2015) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.5b00082 · Cited by 112
Kahl, B. S., Hamadani, M., Radford, J. A., Carlo‐Stella, C., Caimi, P. F., Reid, E. G., Feingold, J. M., Ardeshna, K. M., Solh, M., Heffner, L. T., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-0711 · Cited by 111
Smith, L. M., Nesterova, A., Alley, S. C., Torgov, M. Y., & Carter, P. J. (2006) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-06-0026 · Cited by 108
A Review of Mirvetuximab Soravtansine in the Treatment of Platinum-Resistant Ovarian Cancer
Moore, K. N., Martin, L. P., O’Malley, D. M., Matulonis, U. A., Konner, J. A., Vergote, I. B., Ponte, J. F., & Birrer, M. J. (2017) · Future Oncology · doi:10.2217/fon-2017-0379 · Cited by 108
Gemtuzumab Ozogamicin: Time to Resurrect?
Ravandi, F., Estey, E. H., Appelbaum, F. R., Lo‐Coco, F., Schiffer, C. A., Larson, R. A., Burnett, A. K., & Kantarjian, H. M. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2012.43.0132 · Cited by 104
Walter, R. B., Raden, B. W., Cronk, M. R., Bernstein, I. D., Appelbaum, F. R., & Banker, D. E. (2004) · Blood · doi:10.1182/blood-2003-11-3825 · Cited by 103
Lamberts, L. E., van Oordt, C. W. M. D. H., ter Weele, E. J., Bensch, F., Smeenk, M. M., Voortman, J., Hoekstra, O. S., Williams, S. P., Fine, B. M., Maslyar, D. J., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-1272 · Cited by 100
Cheng, X., Li, J., Tanaka, K., Majumder, U., Milinichik, A. Z., Verdi, A., Maddage, C. J., Rybinski, K. A., Fernando, S., Fernando, D., et al. (2018) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-17-1215 · Cited by 100
Ott, P. A., Hamid, O., Pavlick, A. C., Kluger, H. M., Kim, K. B., Boasberg, P. D., Simantov, R., Crowley, E. M., Green, J. A., Hawthorne, T. R., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.54.8115 · Cited by 97
Scott, A. M., Geleick, D., Rubira, M. R., Clarke, K., Nice, E. C., Smyth, F. E., Stockert, E., Richards, E. C., Carr, F. J., Harris, W. J., et al. (2000) · PubMed · Cited by 97
Self-citationDeckert, J., Park, P. U., Chicklas, S., Yi, Y., Li, M., Lai, K. C., Mayo, M., Carrigan, C. N., Erickson, H. K., Pinkas, J., et al. (2013) · Blood · doi:10.1182/blood-2013-05-505685 · Cited by 94
Kinneer, K., Meekin, J. H., Tiberghien, A. C., Tai, Y., Phipps, S. S., Kiefer, C. M., Rebelatto, M. C., Dimasi, N., Moriarty, A. D., Papadopoulos, K. P., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-1300 · Cited by 92
Site specific protein labeling by enzymatic posttranslational modification
Sünbül, M., & Yin, J. (2009) · Organic & Biomolecular Chemistry · doi:10.1039/b908687k · Cited by 90
Advances in Antibody–Drug Conjugate Design: Current Clinical Landscape and Future Innovations
Gauzy, L., Sassoon, I., & Brun, M. (2020) · SLAS DISCOVERY · doi:10.1177/2472555220912955 · Cited by 90
Socinski, M. A., Kaye, F. J., Spigel, D. R., Kudrik, F. J., Ponce, S., Ellis, P. M., Majem, M., Lorigan, P. C., Gandhi, L., Gutierrez, M. E., et al. (2016) · Clinical Lung Cancer · doi:10.1016/j.cllc.2016.09.002 · Cited by 87
Jagannath, S., Heffner, L. T., Ailawadhi, S., Munshi, N. C., Zimmerman, T. M., Rosenblatt, J., Lonial, S., Chanan-Khan, A., Ruehle, M., Rharbaoui, F., et al. (2019) · Clinical Lymphoma Myeloma and Leukemia · doi:10.1016/j.clml.2019.02.006 · Cited by 85
Ingle, G. S., Chan, P., Elliott, J. M., Chang, W. S., Koeppen, H., Stéphan, J.-P., & Scales, S. J. (2007) · British Journal of Haematology · doi:10.1111/j.1365-2141.2007.06883.x · Cited by 83
Khera, E., & Thurber, G. M. (2018) · BioDrugs · doi:10.1007/s40259-018-0302-5 · Cited by 80
Dillman, R. O., Johnson, D. E., Shawler, D. L., & Koziol, J. (1988) · PubMed · Cited by 77
Herbertson, R. A., Tebbutt, N. C., Lee, F.-T., MACFARLANE, D. J., Chappell, B., Micallef, N., Lee, S.-T., Saunder, T., Hopkins, W., Smyth, F. E., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-0536 · Cited by 74
Self-citationLi, X., Zhou, S., Abrahams, C. L., Krimm, S., Smith, J., Bajjuri, K. M., Stephenson, H. T., Henningsen, R. A., Hanson, J., Heibeck, T. H., et al. (2022) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-22-0322 · Cited by 72
Gymnopoulos, M., Betancourt, O., Blot, V., Fujita, R., Galvan, D., Lieuw, V., Nguyen, S., Snedden, J., Stewart, C., Villicana, J., et al. (2019) · Molecular Oncology · doi:10.1002/1878-0261.12600 · Cited by 69
Recent Advances in the Development of Antineoplastic Agents Derived from Natural Products
Trendowski, M. R. (2015) · Drugs · doi:10.1007/s40265-015-0489-4 · Cited by 67
Whiteman, K. R., Johnson, H. A., Mayo, M., Audette, C. A., Carrigan, C. N., LaBelle, A., Zukerberg, L. R., Lambert, J. M., & Lutz, R. J. (2014) · mAbs · doi:10.4161/mabs.27756 · Cited by 66
Boghaert, E. R., Sridharan, L., Armellino, D. C., Khandke, K. M., DiJoseph, J. F., Kunz, A., Dougher, M. M., Jiang, F., Kalyandrug, L. B., Hamann, P. R., et al. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-0037 · Cited by 66
Merkel Cell Carcinoma: Emerging Biology, Current Approaches, and Future Directions
Tothill, R. W., Estall, V., & Rischin, D. (2015) · American Society of Clinical Oncology Educational Book · doi:10.14694/edbook_am.2015.35.e519 · Cited by 65
Application of Immuno-PET in Antibody–Drug Conjugate Development
Carmon, K. S., & Azhdarinia, A. (2018) · Molecular Imaging · doi:10.1177/1536012118801223 · Cited by 62
Iida, K., Ahmed, A. H. A., Nagatsuma, A. K., Shibutani, T., Yasuda, S., Kitamura, M., Hattori, C., Abe, M., Hasegawa, J., Iguchi, T., et al. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-1434 · Cited by 59
Inotuzumab: from preclinical development to success in B-cell acute lymphoblastic leukemia
Wynne, J. P., Wright, D., & Stock, W. (2019) · Blood Advances · doi:10.1182/bloodadvances.2018026211 · Cited by 58
Al-Rohil, R. N., Torres-Cabala, C. A., Patel, A. B., Tetzlaff, M. T., Ivan, D. S., Nagarajan, P., Curry, J. L., Miranda, R. N., Duvic, M. A., Prieto, V. G., et al. (2016) · Journal of Cutaneous Pathology · doi:10.1111/cup.12797 · Cited by 56
Kigawa, J., Minagawa, Y., Kanamori, Y., Itamochi, H., Cheng, X., Okada, M., Oishi, T., & Terakawa, N. (1998) · Cancer · Cited by 54
Hamblett, K., Barnscher, S. D., Davies, R., Hammond, P., Hernandez, A., Wickman, G., Fung, V., Ding, T., Garnett, G. A. E., Galey, A., et al. (2019) · Cancer Research · doi:10.1158/1538-7445.sabcs18-p6-17-13 · Cited by 53
Anderson, M. G., Falls, H. D., Mitten, M. J., Oleksijew, A., Vaidya, K. S., Boghaert, E. R., Gao, W., Palma, J. P., Cao, D., Chia, P.-L., et al. (2020) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-20-0149 · Cited by 49
Self-citationShen, W., Ballou, B. T., Ryser, H. J. ‐., & Hakala, T. R. (1986) · PubMed · Cited by 48
San Antonio Breast Cancer Symposium 2019
Gourd, K. (2019) · The Lancet Oncology · doi:10.1016/s1470-2045(19)30830-7 · Cited by 47
Preclinical safety profile of disitamab vedotin:a novel anti-HER2 antibody conjugated with MMAE
Jiang, J., Li, S., Shan, X., Wang, L., Ma, J., Huang, M., Dong, L., & Chen, F. (2019) · Toxicology Letters · doi:10.1016/j.toxlet.2019.12.027 · Cited by 45
Kelly, K. R., Chanan-Khan, A. A., Heffner, L. T., Somlo, G., Siegel, D. S. D., Zimmerman, T. M., Karnad, A. B., Munshi, N. C., Jagannath, S., Greenberg, A. L., et al. (2014) · Blood · doi:10.1182/blood.v124.21.4736.4736 · Cited by 44
Antibody-mediated delivery of therapeutics for cancer therapy
Parakh, S., Parslow, A. C., Gan, H. K., & Scott, A. M. (2015) · Expert Opinion on Drug Delivery · doi:10.1517/17425247.2016.1124854 · Cited by 44
Self-citationSaito, S., Namisaki, H., Hiraishi, K., Takahashi, N., & Iida, S. (2019) · Protein Science · doi:10.1002/pro.3598 · Cited by 39
Development of Antibody–Drug Conjugates Using DDS and Molecular Imaging
Yasunaga, M., Manabe, S., Tsuji, A. B., Furuta, M., Ogata, K., Koga, Y., Saga, T., & Matsumura, Y. (2017) · Bioengineering · doi:10.3390/bioengineering4030078 · Cited by 35
Marine Antibody–Drug Conjugates: Design Strategies and Research Progress
Wang, Y.-J., Li, Y., Liu, X., Lu, X., Cao, X., & Jiao, B. (2017) · Marine Drugs · doi:10.3390/md15010018 · Cited by 34
Snyder, J., Malinao, M.-C., Dugal‐Tessier, J., Atkinson, J. E., Anand, B. S., Okada, A., & Mendelsohn, B. A. (2018) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.8b00225 · Cited by 34
ImmunoPET helps predicting the efficacy of antibody-drug conjugates targeting TENB2 and STEAP1
Williams, S., Ogasawara, A. K., Tinianow, J. N., Flores, J. E., Kan, D., Lau, J., Go, M., Vanderbilt, A. N., Gill, H. S., Li, M., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.8390 · Cited by 33
A safety evaluation of brentuximab vedotin for the treatment of Hodgkin lymphoma
Oak, E., & Bartlett, N. L. (2016) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2016.1179277 · Cited by 32
Anti‐CD22 and anti‐CD79b antibody‐drug conjugates preferentially target proliferating B cells
Fuh, F. K., Looney, C., Li, D., Poon, K. A., Dere, R. C., Danilenko, D. M., McBride, J., Reed, C., Chung, S., Zheng, B., et al. (2016) · British Journal of Pharmacology · doi:10.1111/bph.13697 · Cited by 31
L’Italien, L., Orozco, O. E., Abrams, T. J., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-3786 · Cited by 31
Akla, B., Broussas, M., Loukili, N. H., Robert, A., Beau‐Larvor, C., Malissard, M., Boute, N., Champion, T., Haeuw, J., Beck, A., et al. (2019) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-19-0219 · Cited by 31
Johnson, D. A., & Laguzza, B. C. (1987) · PubMed · Cited by 30
Thompson, J. A., Motzer, R. J., Molina, A. M., Choueiri, T. K., Heath, E. I., Kollmannsberger, C., Redman, B. G., Sangha, R. S., Ernst, D. S., Пили, Р., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.33.15_suppl.2503 · Cited by 25
MEN1309/OBT076, a First-In-Class Antibody–Drug Conjugate Targeting CD205 in Solid Tumors
Merlino, G., Fiascarelli, A., Bigioni, M., Bressan, A., Carrisi, C., Bellarosa, D., Salerno, M., Bugianesi, R., Manno, R., Morales, C. B., et al. (2019) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-18-0624 · Cited by 24
The immunoglobulin hinge (Interdomain) region
Adlersberg, J. B. (1976) · La Ricerca in Clinica e in Laboratorio · doi:10.1007/bf02899970 · Cited by 23
Azhdarinia, A., Voss, J., Ghosh, S. C., Simien, J., Vargas, S. H., Cui, J., Yu, W., Liu, Q., & Carmon, K. S. (2018) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.8b00275 · Cited by 23
Gan, H. K., Papadopoulos, K. P., Fichtel, L., Lassman, A. B., Merrell, R. T., van den Bent, M. J., Kumthekar, P., Scott, A. M., Pedersen, M., Gomez, E. J., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.33.15_suppl.2016 · Cited by 21
Self-citationPetrylak, D. P., Smith, D. C., Appleman, L. J., Fleming, M. T., Hussain, A., Dreicer, R., Sartor, O. A., Shore, N. D., Vogelzang, N. J., Youssoufian, H., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2014.32.4_suppl.83 · Cited by 20
Goff, L. W., Papadopoulos, K. P., Posey, J. A., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.27.15_suppl.e15625 · Cited by 18
Cited by
Emerging new therapeutic antibody derivatives for cancer treatment
Jin, S., Sun, Y., Liang, X., Gu, X., Ning, J., Xu, Y., Chen, S., & Pan, L. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00868-x · Cited by 459
Mechanisms of ADC Toxicity and Strategies to Increase ADC Tolerability
Nguyen, T. D., Bordeau, B. M., & Balthasar, J. P. (2023) · Cancers · doi:10.3390/cancers15030713 · Cited by 441
Antibody–Drug Conjugates (ADCs): current and future biopharmaceuticals
Wang, R., Hu, B., Pan, Z., Mo, C., Zhao, X., Liu, G., Hou, P., Cui, Q., Xu, Z., Wang, W., et al. (2025) · Journal of Hematology & Oncology · doi:10.1186/s13045-025-01704-3 · Cited by 285
Zhu, Y., Liu, K., Wang, K., & Zhu, H. (2023) · Cancer · doi:10.1002/cncr.34507 · Cited by 192
Targeting CLDN18.2 in cancers of the gastrointestinal tract: new drugs and new indications
Chen, J., Xu, Z., Hu, C., Zhang, S., Zi, M., Yuan, L., & Cheng, X. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1132319 · Cited by 78
Metadata
- Authors
- Hafeez, U., Parakh, S., Gan, H. K., & Scott, A. M.
- Venue
- Molecules
- Publisher
- MDPI AG
- Published
- 2020-10-16
- Volume
- 25
- Issue
- 20
- Pages
- 4764
- ISSN
- 1420-3049 (ISSN-L)
- OpenAlex
- W3093149563
- Cited by
- 395
- References
- 210
- FWCI
- 21.40
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.